{
    "Trade/Device Name(s)": [
        "Status DS\u2122 OXY"
    ],
    "Submitter Information": "Princeton BioMeditech Corporation",
    "510(k) Number": "K130650",
    "Predicate Device Reference 510(k) Number(s)": [
        "K060351"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG"
    ],
    "Summary Letter Date": "January 10, 2014",
    "Summary Letter Received Date": "January 13, 2014",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Oxycodone"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "DXpress Reader"
    ],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay"
    ],
    "Methodologies": [
        "Solid phase chromatographic immunoassay"
    ],
    "Submission Type(s)": [
        "Test"
    ],
    "Document Summary": "FDA 510(k) summary for Status DS\u2122 OXY rapid, qualitative urine test for oxycodone detection by Princeton BioMeditech",
    "Indications for Use Summary": "Qualitative detection of oxycodone in urine samples for clinical laboratory use only; provides preliminary analytical result, requiring confirmatory testing.",
    "fda_folder": "Toxicology"
}